Her-2/neu Activation and Trastuzumab Treatment in Breast Cancer
Author Information
Author(s): Hudelist G, Köstler W J, Attems J, Czerwenka K, Müller R, Manavi M, Steger G G, Kubista E, Zielinski C C, Singer C F
Primary Institution: University Hospital, Vienna, Austria
Hypothesis
Is there a correlation between Her-2/neu cleavage and tyrosine kinase activity in breast cancer, and how does this affect trastuzumab treatment efficacy?
Conclusion
The study found that active Her-2/neu signaling, indicated by phosphorylation, is associated with better outcomes in patients treated with trastuzumab.
Supporting Evidence
- Patients with phosphorylated Her-2/neu had higher serum Her-2/neu ECD levels.
- Progression-free survival was significantly longer in patients with phosphorylated Her-2/neu.
- Response rates to trastuzumab tended to be higher in patients with active Her-2/neu signaling.
Takeaway
This study shows that a specific part of a cancer protein can help doctors know if a treatment will work better for patients with breast cancer.
Methodology
The study analyzed 62 patients with Her-2/neu overexpressing metastatic breast cancer who received trastuzumab treatment, assessing their Her-2/neu phosphorylation status and clinical outcomes.
Potential Biases
Potential biases in patient selection and treatment protocols may affect the results.
Limitations
The study was retrospective and had a relatively small sample size.
Participant Demographics
Median age of participants was 52.6 years, with a range from 27.6 to 80.9 years.
Statistical Information
P-Value
0.010
Confidence Interval
95% CI 2.5–8.9 for progression-free survival; 95% CI 16.7–30.8 for overall survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website